Table I.
Clinical data of the cases evaluated in this study.
| Characteristics | FBR (n=10) | IDC (n=10) | Control (n=8) |
|---|---|---|---|
| Mean age ± SD, years | 41.3±16.3 | 49.7±14.7 | 47.4±8.0 |
| Ethnicitya, n (%) | |||
| White | 7 (70.0) | 3 (30.0) | 7 (87.5) |
| Black/Mixed | 1 (10.0) | 3 (40.0) | 1 (12.5) |
| NI | 2 (20.0) | 4 (40.0) | 0 (0.0) |
| Menarche, n (%) | |||
| ≤12 years | 4 (40.0) | 3 (30.0) | 5 (62.5) |
| >12 years | 4 (40.0) | 4 (40.0) | 3 (37.5) |
| NI | 2 (20.0) | 3 (30.0) | 0 (0.0) |
| Menopause, n (%) | |||
| <45 years | 0 (0.0) | 1 (10.0) | 2 (25.0) |
| ≥45 years | 2 (20.0) | 3 (30.0) | 3 (37.5) |
| NI | 1 (10.0) | 2 (20.0) | 0 (0.0) |
| NM | 7 (70.0) | 4 (40.0) | 3 (37.5) |
| Children, n (%) | |||
| No child | 5 (50.0) | 3 (30.0) | 2 (25.0) |
| 1 | 1 (10.0) | 2 (20.0) | 2 (25.0) |
| 2 | 2 (20.0) | 1 (10.0) | 2 (25.0) |
| ≥3 | 1 (10.0) | 3 (30.0) | 1 (12.5) |
| NI | 1 (10.0) | 1 (10.0) | 1 (12.5) |
| Oral contraceptive use, n (%) | |||
| Yes | 7 (70.0) | 3 (30.0) | 7 (87.5) |
| No | 1 (10.0) | 5 (50.0) | 1 (12.5) |
| NI | 2 (20.0) | 2 (20.0) | 0 (0.0) |
| History of breast/ovarian cancer, n (%) | |||
| Yes | 7 (70.0) | 2 (20.0) | 4 (50.0) |
| No | 1 (10.0) | 5 (50.0) | 4 (50.0) |
| NI | 2 (20.0) | 3 (30.0) | 0 (0.0) |
| Alcoholism, n (%) | |||
| Yes | 4 (40.0) | 1 (10.0) | 2 (25.0) |
| No | 4 (40.0) | 7 (70.0) | 6 (75.0) |
| NI | 2 (20.0) | 2 (20.0) | 0 (0.0) |
| Smoking, n (%) | |||
| Yes | 1 (10.0) | 3 (30.0) | 4 (50.0) |
| No | 7 (70.0) | 5 (50.0) | 4 (50.0) |
| NI | 2 (20.0) | 2 (20.0) | 0 (0.0) |
| Lymph node infiltrationb, n (%) | |||
| Yes | – | 5 (50.0) | – |
| No | – | 2 (20.0) | – |
| NI | – | 3 (30.0) | – |
a
Ethnicity was self-declared
b
Sentinel lymph node infiltration. SD, standard deviation; FBR, fibroadenoma; IDC, infiltrative ductal carcinoma; NI, not informed; NM, not menopausal.